371 related articles for article (PubMed ID: 14633274)
1. Systematic reviews: a cross-sectional study of location and citation counts.
Montori VM; Wilczynski NL; Morgan D; Haynes RB;
BMC Med; 2003 Nov; 1():2. PubMed ID: 14633274
[TBL] [Abstract][Full Text] [Related]
2. Bibliometrics of systematic reviews: analysis of citation rates and journal impact factors.
Royle P; Kandala NB; Barnard K; Waugh N
Syst Rev; 2013 Sep; 2():74. PubMed ID: 24028376
[TBL] [Abstract][Full Text] [Related]
3. Cochrane systematic reviews and co-publication: dissemination of evidence on interventions for ophthalmic conditions.
Wang X; Hawkins BS; Dickersin K
Syst Rev; 2015 Sep; 4():118. PubMed ID: 26395078
[TBL] [Abstract][Full Text] [Related]
4. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report.
Clarke M; Hopewell S; Chalmers I
J R Soc Med; 2007 Apr; 100(4):187-90. PubMed ID: 17404342
[TBL] [Abstract][Full Text] [Related]
5. Bibliometric analysis of nursing education reviews.
Oermann MH; Bailey HE; Carter-Templeton H; Condy C; Wrigley J; Ledbetter LS
Nurse Educ Today; 2024 Aug; 139():106217. PubMed ID: 38676961
[TBL] [Abstract][Full Text] [Related]
6. Background styles in systematic review articles are not related to the publication in high-impact-factor journals: A meta-epidemiological study.
Kataoka Y; Taito S; Yamamoto-Kataoka S; Tsujimoto Y; Yamazaki H; Furukawa TA
Medicine (Baltimore); 2020 Dec; 99(51):e23801. PubMed ID: 33371154
[TBL] [Abstract][Full Text] [Related]
7. Citations for Randomized Controlled Trials in Sepsis Literature: The Halo Effect Caused by Journal Impact Factor.
Zhang Z; Poucke SV
PLoS One; 2017; 12(1):e0169398. PubMed ID: 28046105
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of Cochrane and non-Cochrane reviews over three decades.
Andersen MZ; Zeinert P; Rosenberg J; Fonnes S
Syst Rev; 2024 May; 13(1):120. PubMed ID: 38698429
[TBL] [Abstract][Full Text] [Related]
9. Motivating authors to update systematic reviews: practical strategies from a behavioural science perspective.
Ervin AM
Paediatr Perinat Epidemiol; 2008 Jan; 22 Suppl 1(0 1):33-7. PubMed ID: 18237350
[TBL] [Abstract][Full Text] [Related]
10. Role of citation tracking in updating of systematic reviews.
Choong MK; Tsafnat G
AMIA Jt Summits Transl Sci Proc; 2014; 2014():18. PubMed ID: 25954571
[TBL] [Abstract][Full Text] [Related]
11. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
Polansky H; Lori G
J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.
Polansky H; Javaherian A; Itzkovitz E
J Evid Based Integr Med; 2018; 23():2515690X18806269. PubMed ID: 30362389
[TBL] [Abstract][Full Text] [Related]
13. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir.
Polansky H; Javaherian A; Itzkovitz E
Drug Des Devel Ther; 2016; 10():2713-22. PubMed ID: 27621592
[TBL] [Abstract][Full Text] [Related]
14. How latent viruses cause breast cancer: An explanation based on the microcompetition model.
Polansky H; Schwab H
Bosn J Basic Med Sci; 2019 Aug; 19(3):221-226. PubMed ID: 30579323
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.
Polansky H; Itzkovitz E; Javaherian A
Drug Des Devel Ther; 2017; 11():575-583. PubMed ID: 28424535
[TBL] [Abstract][Full Text] [Related]
16. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.
Polansky H; Itzkovitz E; Javaherian A
Clin Transl Med; 2016 Dec; 5(1):40. PubMed ID: 27766602
[TBL] [Abstract][Full Text] [Related]
17. Male-pattern baldness, common latent viruses, and microcompetition.
Polansky H; Kestenbaum EH
J Cosmet Dermatol; 2018 Dec; 17(6):1286-1287. PubMed ID: 30019525
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection.
Polansky H; Lori G
Int J Antimicrob Agents; 2020 Jun; 55(6):105971. PubMed ID: 32283177
[No Abstract] [Full Text] [Related]
19. Copy number of latent viruses, oncogenicity, and the microcompetition model.
Polansky H; Schwab H
Oncotarget; 2018 Aug; 9(60):31568-31569. PubMed ID: 30167078
[No Abstract] [Full Text] [Related]
20. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
